Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
179
resultados
Última actualización
02/11/2026 [08:44:00]
Resumen de: US20260341456A1
A medication delivery system, including a wearable device configured to automatically deliver medication based on food order information received from a user computing device. The medication is delivered via a pump, and the medication may be insulin. The food order information includes timing information and/or information about the food ordered necessary to change a medication delivery. A controller determines a medication adjustment based on an estimated physiological response to the food order information. A delivery pump automatically delivers the medication, e.g., an insulin bolus, prior to or in anticipation of food consumption.
Resumen de: US20260334822A1
According to some embodiments, a device for determining a glucose level of a patient comprises a set of electrodes comprising a first working electrode, a second working electrode, a counter electrode, and a reference electrode; and one or more processors. The one or more processors may be configured to: determine a sensor signal based on current flowing between the first working electrode and the counter electrode; determine an open circuit potential (OCP) signal based on a voltage across the second working electrode and the reference electrode while the second working electrode is in an OCP measurement mode and while the first working electrode is in a measurement mode for measuring the sensor signal indicative of the glucose level of the patient; and determine the glucose level of the patient based on the sensor signal and the OCP signal by correcting the sensor signal based on the OCP signal.
Resumen de: US20260334855A1
The present disclosure provides apparatuses and methods for measuring capacitance as an indication of susceptibility to the formation of a diabetic foot ulcer.
Resumen de: US20260334823A1
A method, system, and device for improving the accuracy of a continuous glucose monitoring sensor by estimating a CGM signal at a time t+PH using a value of CGM at time t, using a real-time short-time glucose prediction horizon to estimate the real time denoised CGM value with a noise estimation algorithm.
Resumen de: US20260338727A1
An analyte sensor includes a microcontroller, a base layer, a conductive layer disposed on the base layer where the conductive layer includes a working electrode configured to provide a current signal in presence of glucose, an interference rejection membrane (“IRM”) layer disposed on the working electrode where the IRM layer is negatively charged, and an enzyme layer disposed on the IRM layer where the enzyme layer includes an enzyme selected to generate a detectable electrical signal upon exposure to the glucose. The microcontroller is configured to process an electrochemical impedance spectroscopy (EIS) parameter to determine a state of the IRM layer.
Resumen de: US20260334889A1
Systems and methods for providing sensitive and specific alarms indicative of glycemic condition are provided herein. In an embodiment, a method of processing sensor data by a continuous analyte sensor includes: evaluating sensor data using a first function to determine whether a real time glucose value meets a first threshold; evaluating sensor data using a second function to determine whether a predicted glucose value meets a second threshold; activating a hypoglycemic indicator if either the first threshold is met or if the second threshold is predicted to be met; and providing an output based on the activated hypoglycemic indicator.
Resumen de: WO2026226575A1
Insulin pumps, and systems and methods for delivering insulin to a subject using such pumps. The device includes a control housing including an electromagnetic coil and a controller; and a reservoir housing including a first storage chamber containing insulin, a second delivery' chamber including a magnetic actuator, and an outlet, a first valve between the first and second chambers, and a second valve between the second chamber and the outlet. The reservoir housing is connected to the control housing such that the magnetic actuator is operatively coupled to the electromagnetic coil, and the controller activates the electromagnetic coil to direct the magnetic actuator from a neutral position to a first delivery position, causing insulin within the second chamber to pass through the second valve out the outlet, and a second refill position, causing insulin with the first chamber to pass through the first valve into the second chamber.
Resumen de: US20260335548A1
The exemplary embodiments may provide an accurate prediction of a glycemic outcome for a user of a medicament delivery device, such as an insulin patch pump, when a change is made to the therapy provided by the medicament delivery device. The exemplary embodiments may provide a number of different simulation scenarios and may simulate these scenarios with current control method settings to yield predicted glycemic outcomes for each scenario. The exemplary embodiments may then seek to determine a weighted sum of the predicted glycemic outcomes of the scenarios that most closely matches an actual glycemic outcome as found in a glucose level history of the user. The weights and the in silico user associated with the chosen weighted sum are used in a simulation with a modified insulin therapy to produce a predicted glycemic outcome for the modified insulin therapy.
Resumen de: WO2026225549A1
The present invention addresses the problem of providing: a culture medium for culturing mesenchymal stem cells and a culture medium kit for culturing mesenchymal stem cells, which are capable of maintaining the proliferation ability and cartilage substrate production ability of mesenchymal stem cells even after repeated subculturing; a culture medium additive; and a method for producing a cell therapeutic agent. The present invention provides a culture medium for culturing mesenchymal stem cells, the culture medium containing one or more selected from the group consisting of titanium, vanadium, rubidium, strontium, and barium, containing a human platelet lysate and insulin-like growth factor 2, and free from components derived from a species other than humans.
Resumen de: AU2026249025A1
The exemplary embodiments may provide a drug delivery device that receives glucose level values for a user (e.g., a diabetic patient) and based on the glucose level values, determines when the user has consumed a meal. In some embodiments, the drug delivery device may calculate an appropriate bolus dose and automatically deliver the drug bolus to the user. In some embodiments, instead of detecting the meal, the user may announce the meal, such as by activating an element on the drug delivery device or on a management device for the drug delivery device. Responsive to the meal announcement, the drug delivery device may calculate the drug bolus dose and deliver the drug bolus. In conjunction with the delivery of the drug bolus, the drug delivery device may relax one or more safety constraints for a relaxation period following the drug bolus delivery so that additional basal drug may be delivered, if needed, under relaxed constraints. ct c t
Resumen de: US20260334821A1
The present technology relates to a measurement device that enables accurate measurement of the concentration of glucose (glucose sugar) contained in a measurement target, and a measurement method. The glucose concentration in the measurement target is calculated on the basis of the complex dielectric constant of the measurement target and the moisture content of the measurement target. The moisture content can be calculated on the basis of an incident signal as an electromagnetic wave that has entered the measurement target, and a reflected signal reflected from the measurement target with respect to the incident signal.
Resumen de: US20260337551A1
It is provided a cell macroencapsulation device for implanting cells in a recipient comprising cells encapsulated in a porous membrane, wherein the porous membrane consists of a sugar network coated with a polymeric solution comprising porogen, which can be used as a graft to transplant islets while protecting the graft from the immune system as well as providing enhanced convection and diffusion to ensure long-term cell survival and physiological insulin delivery.
Resumen de: WO2026224483A1
The invention relates to an electronically controlled cooling and heating device for receiving at least one storage device containing a liquid medicament, in particular insulin pen(s) (14), and for maintaining the medicament at a predetermined temperature, as well as to an associated control method. The apparatus according to the invention comprises a housing (2), at least one opening (12) for receiving the at least one storage device containing a liquid medicament, a heat transfer element (9), a Peltier element (10) contacting the heat transfer element, a thermistor (11) arranged between the heat transfer element (9) and the Peltier element (10), a sensor for measuring the current flowing through the Peltier element (10), and a microcontroller. The microcontroller estimates the temperature of the stored medicament as the sum of the temperature measured on the inner side of the Peltier element (10) and a dynamic correction value formed from the measured current, and, on the basis of the estimated temperature, determines the PWM duty cycle of the circuit driving the Peltier element (10).
Resumen de: WO2026224516A1
The present device for infusion and transfusion therapy relates to medicine, and more particularly to infusion and transfusion procedures using activated medicinal solutions, and may be used for administering large quantities of liquids, such as, inter alia, physiological solutions, blood, and glucose. The device comprises: an intravenous drip consisting of a hermetically sealed bag containing a medicinal solution, and a medical tube connected to an outlet of the hermetically sealed bag by a needle; an injection cannula; and an activator for the medicinal solution, the activator being situated between the hermetically sealed bag containing the medicinal solution and the injection cannula. The activator is in the form of an elongated plastic thin-walled bag of an activating fluid, inside which is a plastic thin-walled hollow container having an inlet which is connected by a first medical tube to the outlet of the intravenous drip, and an outlet which is connected by a second medical tube to the injection cannula. The elongated plastic thin-walled bag has a port for the introduction of components of the activating fluid. The activating fluid is hydrogen-activated (enriched) water having a temperature of 59.5-60.5°C. Each medical tube has a valve for controlling the number of drops of the medical solution being administered.
Resumen de: US20260341170A1
A programmatically generated AI avatar includes a customizable personality module, acting as the embodied interface for a powerful AI “mind” that delivers personalized coaching to improve user health, well-being, and longevity. The system uses machine learning, large language models, and biometric modeling to synthesize real-time, multi-modal health data—including sleep, nutrition, glucose, mood, and activity—and generate forward-prescribed KHAs. Unlike human coaches, it continuously adapts based on context and behavior, targeting the root cause: metabolic dysfunction—namely by restoring healthy, sustainable body composition through the preservation or building of lean muscle mass and reduction of excess fat. KHAs can also be shared with friends or programmatically generated AI avatars, allowing for coordinated action, emotional support, and accountability through social connection—further reinforcing positive behavior and adherence. The system's reinforcement learning engine incorporates both individual response data and anonymized population-level insights to optimize recommendations over time, learning which interventions are most effective for users with similar physiological and behavioral profiles. First validated with Olympic athletes—resulting in measurable improvements and medal-winning outcomes—this system offers a scalable, emotionally intelligent coaching engine that exceeds human capability, designed for the ultimate purpose of supporting sustaina
Resumen de: AU2026249132A1
Abstract A monitoring feature, such as, for example, a pen cap, for an insulin delivery device may include at least one circuit adapted to detect at least one of a capping or decapping of the pen cap from an insulin pen and a processor for using information to the at least one of a capping or decapping of the pen cap. A monitoring feature for an insulin delivery device includes at least one circuit adapted to detect use of the insulin delivery device. Abstract Sensor Sensor wo 2019/118531 Data Data SENSOR SYSTEM SUBSTITUTE SHEET (RULE 26) APPLICATION PCT/US2018/065067 ct c t e n s o r e n s o r a t a a t a ( )
Resumen de: US20250195761A1
0000 Systems and methods are provided for sending a software update to an insulin pump and/or user device used with the insulin pump and selectively enabling and disabling certain functionality (e.g., operations, tasks, functions, and/or features) enabled by the software update and/or settings adjusted by the software update. The software update may be in the form of a software package that is sent from a remote device to all insulin pumps or user devices on an insulin pump network. While all devices may receive the same software update it may be desirable to restrict certain functionality and/or settings for some insulin pumps and/or user devices. The insulin pump, user device associated with the insulin pump, and/or remote device in communication with the user device, may determine whether the functionality in the software update should be disabled or otherwise not enabled for a certain insulin pump and/or user device.
Resumen de: EP4830625A1
0001 A glucagon patch pump designed for managing glucose levels in individuals, particularly those with diabetes. The glucagon patch pump includes a base that attaches to a patient's tissue site, a medication bladder for storing glucagon, a medication pump with a conduit for delivering the medication, and a cannula insertion device that deploys the cannula when glucose levels fall below a predetermined threshold. The system can automatically administer glucagon in response to low glucose levels, reducing the need for second-party intervention and minimizing the risk of prolonged hypoglycemia. The glucagon patch pump can be part of a comprehensive glucose management system that includes a glucose sensor and a processor to monitor and respond to glucose levels.
Resumen de: WO2025137203A1
The present invention relates generally to systems, devices, and methods for in vivo monitoring of an analyte level. In particular, the present invention relates to sensors having saccharides or similar molecules present in glucose-oxidase containing sensing layers to improve sensor stability.
Resumen de: US20260325585A1
Disclosed herein are methods, systems, and compositions for enhancing the effectiveness of β-cell (Beta-cell)-based therapies. Also disclosed herein are methods, systems, and compositions related to identifying, sorting and separating heterogeneous populations of stem cell-derived pancreatic β-cells (sBCs) into more useful and functionally homogeneous cell populations. In many embodiments, the most mature and functional of the sBCs are identified and live-sorted using the cell surface protein Ectonucleoside Triphosphate Diphosphohydrolase-3 (ENTP3), which is also referred to as CD39L3. The presently disclosed methods, systems, and compositions are useful for cell therapies, for example replacement therapy. In many embodiments the disclosed systems, methods, and compositions are useful in treatments for diabetes. In some embodiments, the disclosed methods, systems, and compositions may be useful in treating, preventing, and/or curing diabetes, for example type-1 diabetes.
Resumen de: AU2026242121A1
Recommendations based on continuous glucose monitoring (CGM) are described. Given the number of people that wear CGM systems and because CGM systems produce measurements continuously, a platform that provides a CGM system may have an enormous amount of data. This amount of data is practically, if not actually, impossible for humans to process. In implementations, a CGM platform includes a data analytics platform that obtains glucose measurements provided by a CGM system and also obtains additional data associated with a user. The data analytics platform processes these measurements and the additional data to predict a health indicator by using models. This prediction serves as a basis for generating a recommendation, such as a message recommending the user take action or adopt a behavior to mitigate a predicted negative health condition. ep e p
Resumen de: AU2025255066A1
The present invention relates to a cytidine diphosphocholine glycoside represented by general formula (1), a salt thereof, an N-oxide thereof, a solvate thereof, or the like. (In formula (1), R is a sugar residue.)
Resumen de: US20260325852A1
The present disclosure relates to a device for applying electrical stimulation to biological tissues. Specifically, the present disclosure is related to a device for applying anodal/cathodal biphasic electrical stimulation to beta cells of the pancreas. Through application of biphasic stimulation to beta cells of the pancreas, insulin secretion can be increased in an effort to overcome deficiencies associated with diabetic patients.
Resumen de: AU2025249757A1
A variability metric of glucose level values of a user is calculated for each candidate sleeping time frame in a data set of glucose level values of the user obtained over time for a specified period for each day of multiple days. Each of the candidate sleeping time frames may represent a duration in which the user may have been sleeping. Execution of the programming instructions further may cause the processor to determine a mean or median of the variability metric of the glucose level values in the data set for each candidate sleeping time frame across the days in the specified period, designate a selected one of the candidate sleeping time frames that has the lowest mean or median variability metric as the sleeping time frame, and configure the pump to deliver a sleeping basal rate of the medicament for the designated sleeping time frame.
Nº publicación: AU2026242160A1 22/10/2026
Solicitante:
THOMAS JEFFERSON UNIV
Thomas Jefferson University
Resumen de: AU2026242160A1
The present disclosure relates to compositions and methods for treating liver cancers, especially hepatocellular carcinoma, using antisense (AS) nucleic acids directed against Insulin- like Growth Factor 1 Receptor (IGF-1R). The AS may be administered to the patients systemically, or may be used to produce an autologous cancer cell vaccine. In embodiments, the AS are provided in an implantable irradiated biodiffusion chamber comprising tumor cells and an effective amount of the AS. The chambers are irradiated and implanted in the abdomen of subjects and stimulate an immune response that attacks tumors distally. The compositions and methods disclosed herein may be used to treat many different kinds of liver cancer. ep e p
BOPI
Sede Electrónica
